Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

MDNA

Medicenna Therapeutics (MDNA)

Medicenna Therapeutics Corp
Date:
Sort by:
 Showing the most relevant articles for your search:TSX:MDNA
DateTimeSourceHeadlineSymbolCompany
26/04/202422:16PR Newswire (Canada)L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - MDNATSX:MDNAMedicenna Therapeutics Corp
26/04/202422:14PR Newswire (Canada)Canadian Investment Regulatory Organization Trade Resumption - MDNATSX:MDNAMedicenna Therapeutics Corp
26/04/202422:09PR Newswire (Canada)Suspension de la négociation par l'Organisme canadien de réglementation des investissements - MDNATSX:MDNAMedicenna Therapeutics Corp
26/04/202422:07PR Newswire (Canada)Canadian Investment Regulatory Organization Trading Halt - MDNATSX:MDNAMedicenna Therapeutics Corp
11/06/202021:00PR Newswire (Canada)Medicenna to Present at Raymond James Human Healthcare Innovation ConferenceTSX:MDNAMedicenna Therapeutics Corp
11/06/202021:00PR Newswire (US)Medicenna to Present at Raymond James Human Healthcare Innovation ConferenceTSX:MDNAMedicenna Therapeutics Corp
29/05/202022:15PR Newswire (US)Medicenna Presents Data on MDNA11, an IL-2 Superkine at ASCO 2020TSX:MDNAMedicenna Therapeutics Corp
29/05/202022:15PR Newswire (Canada)Medicenna Presents Data on MDNA11, an IL-2 Superkine at ASCO 2020TSX:MDNAMedicenna Therapeutics Corp
29/05/202022:05PR Newswire (US)Medicenna Updates Efficacy Results from Phase 2b Recurrent GBM Trial at ASCO 2020TSX:MDNAMedicenna Therapeutics Corp
29/05/202022:05PR Newswire (Canada)Medicenna Updates Efficacy Results from Phase 2b Recurrent GBM Trial at ASCO 2020TSX:MDNAMedicenna Therapeutics Corp
15/05/202021:30PR Newswire (US)Medicenna Announces March 31, 2020 Year-End ResultsTSX:MDNAMedicenna Therapeutics Corp
15/05/202021:30PR Newswire (Canada)Medicenna Announces March 31, 2020 Year-End ResultsTSX:MDNAMedicenna Therapeutics Corp
04/05/202021:00PR Newswire (Canada)Medicenna Announces Upcoming Presentations at the ASCO Annual MeetingTSX:MDNAMedicenna Therapeutics Corp
04/05/202021:00PR Newswire (US)Medicenna Announces Upcoming Presentations at the ASCO Annual MeetingTSX:MDNAMedicenna Therapeutics Corp
15/04/202023:23PR Newswire (Canada)Medicenna Announces Full Exercise of Over-Allotment Option as Part of $40.25 Million Public OfferingTSX:MDNAMedicenna Therapeutics Corp
25/03/202022:00PR Newswire (US)Medicenna's IL-2 Superkine, MDNA19, Demonstrates Best-in-Class Features in a Non-Human Primate StudyTSX:MDNAMedicenna Therapeutics Corp
25/03/202022:00PR Newswire (Canada)Medicenna's IL-2 Superkine, MDNA19, Demonstrates Best-in-Class Features in a Non-Human Primate StudyTSX:MDNAMedicenna Therapeutics Corp
18/03/202000:14PR Newswire (Canada)Medicenna Announces Closing of Public Offering of $35 MillionTSX:MDNAMedicenna Therapeutics Corp
13/03/202000:00PR Newswire (Canada)Medicenna Announces Intention to File Final Short Form ProspectusTSX:MDNAMedicenna Therapeutics Corp
05/03/202001:37PR Newswire (Canada)L'OCRCVM permet la reprise de la négociation - MDNATSX:MDNAMedicenna Therapeutics Corp
05/03/202001:36PR Newswire (Canada)IIROC Trade Resumption - MDNATSX:MDNAMedicenna Therapeutics Corp
05/03/202001:25PR Newswire (Canada)Medicenna Announces Pricing of $35 Million Overnight Marketed Offering of Common SharesTSX:MDNAMedicenna Therapeutics Corp
04/03/202009:14PR Newswire (Canada)Suspension de la négociation par l'OCRCVM - MDNATSX:MDNAMedicenna Therapeutics Corp
04/03/202009:11PR Newswire (Canada)IIROC Trading Halt - MDNATSX:MDNAMedicenna Therapeutics Corp
04/03/202008:35PR Newswire (Canada)Medicenna Announces Overnight Marketed Offering of Common SharesTSX:MDNAMedicenna Therapeutics Corp
13/02/202023:30PR Newswire (US)Medicenna Reports Third Quarter Fiscal 2020 Financial ResultsTSX:MDNAMedicenna Therapeutics Corp
13/02/202023:30PR Newswire (Canada)Medicenna Reports Third Quarter Fiscal 2020 Financial ResultsTSX:MDNAMedicenna Therapeutics Corp
13/01/202023:00PR Newswire (US)Medicenna Reports Compelling Results from Recurrent Glioblastoma Trial When Compared to an Eligibility-Matched Control ArmTSX:MDNAMedicenna Therapeutics Corp
13/01/202023:00PR Newswire (Canada)Medicenna Reports Compelling Results from Recurrent Glioblastoma Trial When Compared to an Eligibility-Matched Control ArmTSX:MDNAMedicenna Therapeutics Corp
09/01/202001:13PR Newswire (US)Medicenna Receives $1.3 Million Through Early Warrant ExercisesTSX:MDNAMedicenna Therapeutics Corp
 Showing the most relevant articles for your search:TSX:MDNA